David B. Miklos,


Associate Professor of Medicine
Chief, BMT and Cell Therapy
Stanford University Medical Center
Clinical Director, Cancer Cell Therapy Program
Stanford Health Care
Palo Alto, CA

David B. Miklos, MD, PhD, is an associate professor of medicine and chief of BMT and Cell Therapy at Stanford University Medical Center, as well as the clinical director of the Stanford Cancer Cell Therapy Program. He was an undergraduate at the University of Notre Dame. He earned his MD and a PhD in genetics at Yale Medical School before training as a hematologist-oncologist and bone marrow transplant clinician at the Brigham and Women’s Hospital and the Dana-Farber Cancer Institute at Harvard University. Dr Miklos joined Stanford University in 2004.

His laboratory research has characterized allogeneic B-lymphocyte biology as a pathogenic mechanism in chronic graft-versus-host disease (cGVHD), ABO mismatch complications following allogeneic hematopoietic cell transplantation, tumor immunology, and chimeric antigen receptor (CAR) T-cell therapies. 

Dr Miklos has led 7 investigator-initiated trials and 8 industry-sponsored studies with site principal investigator responsibilities in 15 others. His laboratory research supported anti–B-cell therapy for the management of cGVHD, and he developed and led the PCYC-1129 phase 2 trial that led to the US Food and Drug Administration approval of ibrutinib for patients with cGVHD that have failed prior therapy. He also leads the randomized controlled trial PCYC-1140 testing ibrutinib in patients with new-onset cGVHD.

Over the past 5 years, Dr Miklos has developed the Stanford Cancer Cell Therapy Program with Crystal Mackall, MD, and he especially enjoys studying CAR-T marked cells with cutting-edge single-cell technologies. His work contributed to the US Food and Drug Administration approval of axicabtagene ciloleucel for relapsed and refractory aggressive lymphoma.